Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada (Q79865927)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17335310%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

title

Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17335310%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

1 reference

Daniel T Grima

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17335310%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Melissa F Thompson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17335310%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Luc Sauriol

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17335310%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17335310%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17335310%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17335310%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17335310%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

253-266

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17335310%20AND%20SRC:MED&resulttype=core&format=json

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

26 December 2019

cites work

1 reference

12 December 2020

Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis

1 reference

12 December 2020

Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo

1 reference

12 December 2020

Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes

1 reference

12 December 2020

The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial

1 reference

12 December 2020

Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group

1 reference

12 December 2020

Banting Lecture. Hypoglycemia: the limiting factor in the management of IDDM.

1 reference

12 December 2020

Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

A One-year, Randomised, Multicentre Trial Comparing Insulin Glargine with NPH Insulin in Combination with Oral Agents in Patients with Type 2 Diabetes

1 reference

12 December 2020

Valuing health-related quality of life in diabetes

1 reference

12 December 2020

Correlates of hypoglycemic fear in type I and type II diabetes mellitus.

1 reference

12 December 2020

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Cost of managing complications resulting from type 2 diabetes mellitus in Canada

1 reference

12 December 2020

The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study

1 reference

12 December 2020

Maternal fear of hypoglycemia in their children with insulin dependent diabetes mellitus

1 reference

12 December 2020

Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime

1 reference

12 December 2020

Fear of hypoglycemia in the parents of children and adolescents with diabetes: maladaptive or healthy response?

1 reference

12 December 2020

Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

1 reference

12 December 2020

The psychosocial impact of severe hypoglycemic episodes on spouses of patients with IDDM.

1 reference

12 December 2020

Fear of hypoglycemia: relationship to physical and psychological symptoms in patients with insulin-dependent diabetes mellitus

1 reference

12 December 2020

Hyperglycaemia, hypoglycaemia, and blood glucose control in diabetes: symptom perceptions and treatment strategies

1 reference

12 December 2020

Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients

1 reference

12 December 2020

The effects of insulin glargine treatment and an educational programme on glycaemic control in type 2 diabetes patients in clinical practice

1 reference

12 December 2020

Fears and phobias in people with diabetes.

1 reference

12 December 2020

The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective

1 reference

12 December 2020

Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes

1 reference

12 December 2020

Fear of hypoglycemia: quantification, validation, and utilization

1 reference

12 December 2020

Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine

1 reference

12 December 2020

United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy

1 reference

12 December 2020

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

12 December 2020

Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes

1 reference

12 December 2020

New technologies and potential cost savings related to morbidity and mortality reduction in Class III/IV heart failure patients in Canada

1 reference

12 December 2020

Hypoglycemia in diabetes: common, often unrecognized.

1 reference

12 December 2020

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

1 reference

12 December 2020

Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada

1 reference

12 December 2020

Prognosis and Determinants of Survival in Patients Newly Hospitalized for Heart Failure

1 reference

12 December 2020

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes

1 reference

12 December 2020

Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial

1 reference

12 December 2020

Clinical characteristics of type 1 diabetic patients with and without severe hypoglycemia

1 reference

12 December 2020

Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study).

1 reference

12 December 2020

Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin

1 reference

12 December 2020